Molecular profile of KRAS G12C-mutant colorectal and non-small-cell lung cancer.

ABSTRACT:

Background

KRAS is the most frequently mutated oncogene in cancer, however efforts to develop targeted therapies have been largely unsuccessful. Recently, two small-molecule inhibitors, AMG 510 and MRTX849, have shown promising activity in KRAS G12C-mutant solid tumors. The current study aims to assess the molecular profile of KRAS G12C in colorectal (CRC) and non-small-cell lung cancer (NSCLC) tested in a clinical certified laboratory.

Methods

CRC and NSCLC samples submitted for KRAS testing between 2017 and 2019 were reviewed. CRC samples were tested for KRAS and NRAS by pyrosequencing, while NSCLC samples were submitted to next generation sequencing of KRAS, NRAS, EGFR, and BRAF.

Results

The dataset comprised 4897 CRC and 4686 NSCLC samples. Among CRC samples, KRAS

SUBMITTER: Araujo LH 

PROVIDER: S-EPMC7905642 | biostudies-literature | 2021 Feb

REPOSITORIES: biostudies-literature